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However, whether miR-21-mediated posttranscriptional regulation is involved in antigen presenta-
tion and anti-mycobacterial responses remains unclear. Here, we report that miR-21 can be induced
after Bacillus Calmette-Guerin (BCG) vaccination by NF-kB activation. miR-21 suppressed IL-12 pro-
duction by targeting IL-12p35, which impaired anti-mycobacterial T cell responses both in vitro
and in vivo. Additionally, miR-21 also promoted dendritic cell (DC) apoptosis by targeting Bcl-2.
Therefore, miR-21 may potentially be involved in ﬁne-tuning of the anti-mycobacterial Th1 response
and in regulating the efﬁcacy of BCG vaccination.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mycobacterium tuberculosis (MTB) is estimated to infect one-
third of people all over the world, and cause tuberculosis (TB)
[1,2]. The most commonly used vaccine is an attenuated strain of
Mycobacterium bovis Bacillus Calmette-Guerin (BCG). Unfortu-
nately, the efﬁcacy of this vaccination is variable and protects
few people against MTB infection. The wide spread of TB has been
further aggravated by emerging multidrug-resistant strains of
mycobacteria as well as the AIDS-pandemic [3,4]. Thus, studies
are needed to examine novel TB vaccines and identify adjuvant
components to the BCG vaccine. Till now, some compounds have
already been found to promote the efﬁcacy of BCG vaccination
[5,6]. However, new adjuvant targets are still necessary.
MicroRNAs (miRNAs) are small non-coding RNAs capable of
post-transcriptional gene expression regulation [7]. miRNAs bind
speciﬁcally to the 30 untranslated regions (UTRs) of target mRNAs
to trigger the mRNA degradation or translation inhibition. How-
ever, most studies examining miRNAs have focused on cancer biol-
ogy [8], and the effect of miRNAs on the immune system have onlychemical Societies. Published by E
arrow derived dendritic cell;
cobacterium tuberculosisrecently become evident [9,10]. miR-21 has been identiﬁed as one
of the most highly expressed miRNAs in various tumors [11,12].
Increased miR-21 expression is associated with cell proliferation,
migration, invasion and metastasis, suggesting that miR-21 is a
key regulatory molecule in cancer initiation and/or progression
[11,12]. Recently, miR-21 was also shown to be involved in inﬂam-
matory responses [13], and regulate the immune responses by
targeting programmed cell death 4 (PDCD4) [10,14]. Furthermore,
Lu et al. also revealed that miR-21 can be induced in the lung of
multiple asthma models and regulates the lung eosinophilia, the
Th1/Th2 balance and the prognosis for asthma [15,16]. They also
suggested that miR-21 exerts these functions primarily by target-
ing Il12 mRNA. Because IL-12 is a key cytokine involved in adaptive
immune responses involving Th1 cell polarization, miR-21 may
play an important role in regulating Th1/Th2 immune responses
in general in addition to regulating asthma. However, this needs
to be further validated in other models such as infectious disease
or malignancies.
In this study, we examined the regulation and function of miR-
21 in Mtb infection. We showed that BCG infection can induce de
novo transcription of miR-21 in macrophages and dendritic cells
(DCs) both in vitro and in vivo. This upregulated miR-21 inhibited
IL-12 expression, and thus suppressed host Th1 responses, which
may explain for the low efﬁcacy of BCG vaccination. We also
showed that miR-21 can promote DC apoptosis after BCG infectionlsevier B.V. All rights reserved.
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in antigen presenting cells (APCs) signiﬁcantly promotes anti-
mycobacterial immunity in vivo. Thus, miR-21 may be an effective
mycobacterial strategy that can be used to escape the host immune
response and establish chronic infection, and may also serve as a
potential target to generate more potent protective immunity fol-
lowing BCG vaccination.2. Materials and methods
2.1. Mice and reagents
C57BL/6 mice were purchased from the Zhejiang University
Laboratory Animal Center, and maintained and used in accordance
with the institutional guidelines for animal care. MicroRNAmimics
and inhibitors were purchased from Genepharma (Shanghai,
China). Anti-CD4 (L3T4), anti-CD8 (Ly2), and anti-IFN-c (XMG1.2)
were purchased from BD Pharmingen (San Diego, CA). Puriﬁed pro-
tein derivative (PPD) was from the China Institute of Veterinary
Drug Control.
2.2. Generation of bone marrow-derived macrophages (BMDMs) and
dendritic cells (BMDCs)
BMDCs and BMDMs were generated from wild-type (WT) mice
as described previously [17] with minor modiﬁcations. Brieﬂy,
5  106 bone marrow cells/ml was cultured in RPMI 1640 medium
supplemented with 10% FCS, 2 mM L-glutamine for 6 days. To ob-
tain BMDC, 20 ng/ml GM-CSF and 1 ng/ml IL-4 (R&D Systems) were
added, or 30 ng/ml M-CSF was added to obtain BMDM. On day 3,Fig. 1. BCG infection upregulates miR-21 expression. (A). Expression of miR-21 in lung
compared with those from non-infected mice. (B,C). miR-21 expression in BMDCs infecte
MOI for 24 h by quantitative RT-PCR. (D). BMDCs were stimulated with LTA (10 lg/ml), C
are shown as mean ± SD of three independent experiments. ⁄⁄P < 0.01.non-adherent cells were washed away, and new medium contain-
ing the colony stimulating factors were added.
2.3. Isolation of macrophages from the lung
Lung macrophages were isolated as described previously [18].
Brieﬂy, mouse lung tissue was digested with collagenase and
minced. After lysing RBC, the dissociated cells were underlaid with
15 ml of 35% percoll solution, centrifuged at 2200 rpm for 20 min.
Mononuclear cells were collected and incubated in a 6-well plate
for 2 h. Adherent cells were harvested as lung macrophages.
2.4. Quantitative real-time PCR
MaturemiR-21was detected by Taqman Quantitative Real-Time
PCR using microRNA speciﬁc probes and PCR master mix (Applied
Biosciences, Austin, TX). U6RNB was used as an internal control.
mRNA and pri-/pre- miR-21 transcripts were detected using SYBR
Green Imix (Roche, Lewes, UK). b-Actinwas used as an internal con-
trol. The 2DDCt method was used to calculate fold change.
2.5. Cell transfection
Cells were transfected with miRNA mimics or inhibitor using
INTERFERin (Polyplus-transfection, Illkirch, France) according to
the manufacturer’s instructions. Bcl2 siRNAs were synthesized
(GenePharma, Shanghai, China), and transfected into mouse DCs
using INTERFERin. Transfection of Il12p35 encoding plasmid was
performed using Amaxa Nucleofection Technology (Amaxa, Koeln,
Germany).(left) and alveolar macrophages (right) isolated from mice 7 d post BCG infection,
d with BCG at multiplicity of infection (MOI) 10 for indicated times (B) or at varying
pG ODN (1 lM) or LPS (100 ng/ml) for 12 h, and assayed for miR-21 expression. Data
Fig. 2. BCG induces miR-21 de novo expression via an Erk and NF-jB dependent pathway. (A). BMDCs were infected with BCG for 6 h, and pri- and pre-miR-21 were detected
via qRT-PCR. BMDCs without infection (PBS) were set as control. (B). BMDCs were pretreated with PDTC (NF-kB inhibitor), SP600125 (JNK inhibitor), PD98059 (ERK inhibitor),
or SB203580 (p38 inhibitor) respectively 30 min prior to BCG infection. Cells were collected and assayed for miR-21 expression by qRT-PCR 6 h after BCG infection. (C,D).
BMDCs were pretreated with PDTC or PD98059 with varying concentrations prior to BCG infection, and miR-21 expression were determined. Data are shown as mean ± SD of
three independent experiments. ⁄⁄P < 0.01.
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For luciferase reporter assays, the wild-type 30-UTR of Il12p35
(NM_000882) and Bcl2 (NM_009741.3) from mouse cDNA were
cloned into the pGL3-promotor vector (Promega, Fitchburg, WI).
These reporter vectors were co-transfected with the Renilla vector
pRL-TK into HEK293 cells using lipofectamine 2000 (Invitrogen,
Carlsbad, CA). Luciferase activity was measured using the Dual-
Luciferase Reporter Assay System (Promega).
2.7. Antigen presentation in vitro
Mice were vaccinated intravenously with 1  106 BCG. Two
weeks later, the spleens were dissociated into a single-cell suspen-
sion and isolated of total T cells using Pan T cells enrichment kit
(Miltenyi Biotec, Aubum, CA). A total of 2  105 of these primed
T cells were cultured in 96-well U-bottom plates with BCG-in-
fected BMDCs transfected with miR-21 mimics or inhibitors. After
additional culture for 3 days, the supernatant was collected and as-
sayed for IFN-c level.
2.8. Antigen presentation in vivo
BMDCs (2  106) that had been infected with BCG in vitro were
administered in the footpads to prime T cells in draining lymph
node. Ten days later, 10 lg PPD were injected into right hind foot-
pad, and the left hind footpad was injected with 50 ll PBS. Footpad
thickness was measured 24 h later using a spring-loaded microm-
eter. Swelling was calculated according to the following equation:
right footpad thickness – left footpad thickness. Lymph node cellswere also collected at day 10 and assayed for IFN-c production in
CD4 and CD8 T cells
2.9. Detection of cytokine production
IL-12p70, tumor necrosis factor (TNF), IL-6, IL-1b, IL-10 and IFN-
c production in cell supernatants were measured using ELISA Kits
(R&D systems) according to the manufacturer’s instructions.
2.10. Statistical analysis
Data are expressed as the mean ± SD of experiments performed
in triplicate. Statistical comparisons were performed using Stu-
dent’s t-test.
3. Results
3.1. miR-21 is upregulated in BCG infected APCs
To gain insight into the biological role of miR-21 in BCG vacci-
nation, we compared miR-21 expression in normal and BCG-vacci-
nated mice. BCG-infected lungs showed signiﬁcantly increased
miR-21 expression, compared with non-infected lungs (Fig. 1A).
Because BCG-infected APCs are responsible for the initiation of
anti-mycobacterial T cell immunity, we isolated lung macrophages
following in vivo BCG infection, and found that miR-21 expression
was also upregulated (Fig. 1A). Furthermore, in vitro generated
BMDMs and BMDCs infected with BCG also showed increased
miR-21 expression in a time and dose dependent manner
(Fig. 1B,C and Supplementary Fig. 1).
Fig. 3. miR-21 impairs antigen presentation of APCs. (A,B) BCG-infected BMDCs transfected with miR-21 inhibitors (A) or mimics (B) were co-cultured with sensitized T cells
as described in methods, and supernatant IFN-c, IL-4 and IL-17 were examined using ELISA assay. (C,D) BCG-infected BMDCs transfected with miR-21 mimics (C) or inhibitors
(D) were injected into the footpad of naïve mice. Ten days later, a DTH response to PPD challenge was measured. (E,F) Mice immunized with miR-21 inhibitors (E) or miR-21
mimics (F) transfected BMDCs were killed after 10 days and draining lymph nodes were collected. Intracellular IFN-c cytokine staining was measured by re-stimulation with
anti-CD3 for 6 h with BFA. Data are shown as mean ± SD of three independent experiments. ⁄⁄P < 0.01, ⁄P < 0.05.
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phages and DCs via several toll-like receptors (TLRs), including
TLR2, TLR9 and TLR4 [19,20], and that LPS stimulation induces
miR-21 expression in the murine macrophage cell line RAW264.7
[16]. We further stimulated BMDCs using the TLR agonists lipotei-
choic acid (LTA), CpG-DNA, and lipopolysaccharide (LPS). As shown
in Fig. 1D, activation these TLRs upregulated miR-21 expression.
Our observations suggest that BCG-vaccination induces expression
of miR-21 in APCs by the activation of the TLRs.
3.2. Erk and NF-kB pathways are responsible for miR-21 induction
To determine the exact mechanisms of BCG-induced miR-21
upregulation, we detected pri- and pre-miR-21 in BCG infected
BMDCs. Six hours after infection, both pri- and pre-miR-21 were
signiﬁcantly upregulated (Fig. 2A), suggesting de novo transcription
of miR-21. BCG may activate JNK, ERK, P38 and NF-jB through TLR
activity [21,22]. We next investigated which pathways are involved
in pri-miR-21 transcription in BCG-infected BMDCs. Addition of the
NF-jB inhibitor pyrrolidine dithiocarbamate (PDTC) strongly im-
paired miR-21 expression following BCG infection (Fig. 2B). Fur-
thermore, inhibitor of ERK (PD98059) also inhibited miR-21
expression, while inhibitors of the JNK pathway (SP600125) and
P38 (SB203580) had no effect (Fig. 2B). PD98059 and PDTC inhib-
ited miR-21 expression in a dose-dependent manner (Fig. 2C,D).
These data indicate that BCG infection induces de novo miR-21
expression in APCs primarily through the Erk and NF-kB pathway.
3.3. miR-21 impairs the T cell responses and protective immunity
triggered by BCG-infected APCs
To investigate whether miR-21 inﬂuences the ability of APCs to
initiate a Th1 response, BMDCs transfected with miR-21 mimics orinhibitors were infected with live BCG in vitro (Supplementary
Fig. 2). These cells were then washed and incubated with
antigen-responsive T cells prepared from the spleens of BCG-
immunized mice. After culturing for another 3 days, miR-21
inhibitor-transfected BMDCs triggered a stronger IFN-c production
from T cells (Fig. 3A). However, IL-4 and IL-17 showed little change.
Accordingly, the IFN-c production was signiﬁcantly inhibited in
BMDCs transfected with miR-21 mimics (Fig. 3B). These data
provide further evidence that miR-21 negatively regulates antigen
speciﬁc T cell responses triggered by BCG-vaccinated APCs.
To verify whether miR-21 can modify Th1 responses in vivo,
BMDCs showing differential miR-21 expression were injected into
the footpads of unsensitized mice and tested for their ability to
prime a delayed-type hypersensitivity (DTH) response. After chal-
lenge with PPD, signiﬁcant foot swelling was observed in mice
immunized with miR-21 inhibitor-transfected BMDCs (Fig. 3C).
Intracellular cytokine staining also conﬁrmed more IFN-c produc-
ing CD4 and CD8 T cells in the draining lymph nodes of these mice
(Fig. 3E). The opposite effect was also observed for miR-21 mimics
(Fig. 3D,F). Thus, these data suggest that if APCs are deprived of
miR-21, more potent anti-mycobacterial immune responses may
be induced following BCG vaccination.
3.4. miR-21 reduces IL-12 production in BMDCs
To elucidate the mechanism of miR-21-induced suppression of
APC function, we analyzed the phenotype of APCs vaccinated with
BCG. Expression of MHC and co-stimulating molecules, including
CD80, CD86, and CD40 etc., were similar between miR-21 inhibi-
tor- and control-transfected BMDCs (Supplementary Fig. 3). How-
ever, an ELISA assay revealed that IL-12p70 was signiﬁcantly
increased in BMDCs following miR-21 knockdown (Fig. 4A). Quan-
titative PCR analysis also showed an increased Il12 p35 mRNA level
Fig. 4. Inverse correlation of IL-12 and miR-21 in BCG-infected BMDCs. (A) ELISA assay of IL-12p70, TNF, and IL-6 secretion from BMDCs transfected with miR-21 inhibitors or
controls, and stimulated with BCG for 6 h. (B) Quantitative PCR analysis of Il12p35 and Il12p40 mRNA levels in BCG-infected BMDCs transfected with miR-21 inhibitor or not.
(C) IL-12 protein and Il12p35 mRNA level were determined in BCG-infected BMDCs transfected with miR-21 mimics or not. (D) Expression of Il12p35 mRNA and miR-21
levels was determined by qRT-PCR in BMDCs infected with BCG for indicated times. (E) Correlation analysis between Il12p35 and miR-21 expression in (D). Data are shown as
mean ± SD of three independent experiments. ⁄⁄P < 0.01, ⁄P < 0.05.
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inﬂuenced (Fig. 4B). Consistently, miR-21 mimics further reduced
IL-12p70 protein level and Il12 p35 mRNA expression (Fig. 4C).
We then infected BMDCs in vitro by BCG, and analyzed the ki-
netic expression of endogenous IL-12 and miR-21 mRNA expres-
sion at different time points. Both IL-12 mRNA and miR-21 were
upregulated following infection (Fig. 4D). However, IL-12 tran-
scription increased tens of folds only 1 h after infection, reaching
its peak between 4 and 6 h, while miR-21 increased gradually
and only slightly following infection, and this increase became
more signiﬁcant after 6 h. Overall, miR-21 was negatively corre-
lated with IL-12p35 mRNA expression (Fig. 4E), suggesting post-
transcriptional regulation of Il12p35 by miR-21.
We also examined the expression of TNF, IL-6, IL-1b and IL-10
secretion in miR-21 inhibitor-transfected BMDCs and compared
with control-transfected BMDCs (Fig. 4A and Supplementary
Fig. 4A,B), as recent studies suggested for a protective role of
TNF, IL-6 and IL-1b in host resistance to Mtb infection [23–25],
while IL-10 primarily suppresses anti-mycobacterial responses
[26]. We observed slightly increased expression of TNF, IL-6 and
IL-1b in BMDCs inhibited of miR-21. However, no signiﬁcant alter-
ation was observed in IL-10 expression. But when these BMDCs
were co-cultured with antigen speciﬁc T cells, slightly increased
IL-10 production was observed (Supplementary Fig. 4C). Reports
also suggested that mycobacteria infection may induce IFN-c pro-
duction in DCs by targeting TLRs, which may function in an auto-
crine manner to prime DCs themselves [27,28]. However, the
IFN-c expression by BMDCs was indeed low and showed no differ-
ence after miR-21 inhibition (Supplementary Fig. 4A,B), although
IL-12 and STAT4 are suggested to be responsible for inducing
IFN-c in DCs [29].3.5. miR-21 targets Il12p35 mRNA
Through a bioinformatics search using TargetScan and PicTar,
we found that the 30UTR of Il12p35 mRNA contains the miR-21
binding sites that are very conserved in mammals (Fig. 5A). Addi-
tionally, Il12p40, Tnf, Il6 and Il1b mRNA were not directly included
in the predicted miR-21 targets, suggesting for other mechanisms
involved in miR-21 mediated reduction of these cytokines.
To examine the possibility that IL-12 is regulated post-trans-
criptionally by miR-21, a dual-luciferase reporter assay was used.
Luciferase expression markedly decreased when the reporter plas-
mid containing the Il12p35 30UTR was co-transfected with miR-21
mimics (Fig. 5B). Furthermore, this decrease was abrogated by
transfection of a plasmid containing a three-base mutation in the
miR-21 binding site. miR-21 also signiﬁcantly suppressed lucifer-
ase activity in BMDCs, even after stimulating of BCG (Fig. 5C).
These data indicate that miR-21 can inhibit IL-12 production by di-
rectly targeting the 30UTR of Il12p35 mRNA.
3.6. miR-21 suppresses T cell priming through targeting of IL-12
The above results suggested that miR-21 can downregulate IL-
12 as well as TNF and IL-6. To elucidate which cytokine is respon-
sible for miR-21 induced suppression of APC function, we added
each cytokine exogenously and compared their inﬂuence on the
T cell priming function of BMDCs. As shown in Fig. 5D, adding
exogenous IL-12 increased IFN-c production in control BMDCs to
the same level as that in miR-21-inhibitor transfected BMDCs,
while adding TNF or IL-6 had no effect. However, miR-21-induced
suppression of IL-12 production and T cell priming was abrogated
by overexpression of Il12p35 without the 30UTR sequence (Fig. 5E).
Fig. 5. miR-21 directly targets Il12p35 and Bcl2 transcripts. (A). Alignment of miR-21 and its target sites in the 30UTR of Il12p35 and Bcl2. Underlining indicates the conserved
binding sites or seeding sequence of miR-21. (B). HEK-293 cells were cotransfected with miR-21 mimics or control, together with reporter vectors containing wild-type
(Il112a-WT) or mutated (Il12a-Mut) Il12a 30UTR (left), and Bcl2-WT or Bcl2-Mut 30UTR (right). Luciferase activities were measured after 24 h in cell lysates. (C). BMDCs were
cotransfected with vectors containing the 30UTR of wild-type Il12p35 plus miR-21 mimics, and luciferase activities were detected with (BCG) or without (PBS) BCG infection.
(D) ELISA assay of IFN-c from T cells triggered by BCG-infected BMDCs transfected with miR-21 inhibitor or control, with the addition of exogenous IL-12 (10 ng/ml), TNF
(10 ng/ml) or IL-6 (10 ng/ml). (E) ELISA of IL-12 from BMDCs transfected with Il12p35 plasmid without 30UTR together with miR-21 inhibitor (left), and IFN-c production from
T cells triggered by these BMDCs (right). Data are shown as mean ± SD of three independent experiments. ⁄⁄P < 0.01, ⁄P < 0.05.
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duction by targeting Il12p35 in APCs, contributing to the suppres-
sive function of miR-21 on T cell priming.
3.7. miR-21 promoted apoptosis of DCs by targeting Bcl2
Many studies revealed thatMtb and particularly BCG, can induce
apoptosis of infected cells [30,31]. We further analyzed the apopto-
sis of these BCG-vaccinated BMDCs. As shown in Fig. 6A, BCG infec-
tion indeed induced signiﬁcant apoptosis of DCs. Additionally,
miR-21 mimics further increased BCG-induced apoptosis, while
miR-21 inhibitors signiﬁcantly rescued this activity (Fig. 6A,B), sug-
gesting for an important role of miR-21 in DC apoptosis. Because
Bcl2 has been suggested as another target ofmiR-21 in breast cancer
cells [32] (Fig. 5A,B), and previous study suggested for a role of Bcl-2
in BCG-induced apoptosis [31], we further examined the Bcl-2
expression in BMDCs with varying levels of miR-21 expression. As
shown in Fig. 6C, miR-21 mimics suppressed Bcl-2 mRNA and pro-
tein expression in BCG-infected BMDCs, while the miR-21 inhibitor
showed the opposite effect, revealing an inverse correlation be-
tween Bcl2 and miR-21 expression. However, although miR-21
mimics suppressed Bcl2 expression in BMDCs without BCG infec-
tion, a higher rate of apoptosis in these DCs compared with that in
transfected with control mimics was not observed (Supplementary
Fig. 5 and data not shown).
To determine whether the miR-21 induced downregulation of
Bcl-2 is responsible for the increased BMDC apoptosis, we silencedBcl2 in BMDCs, and found that Bcl2 knockdown abrogated the
proapoptotic role of miR-21 (Fig. 6D), suggesting that induction
of BCG-infected DC apoptosis by miR-21 is due to downregulation
of Bcl-2. Thus, in addition to targeting Il12p35, miR-21 also induces
DC apoptosis by targeting Bcl-2, which may explain the slightly in-
creased production of TNF, IL-6 and IL-1b in miR-21 inhibitor-
transfected BMDCs (Fig. 4A).4. Discussion
miR-21 is a broadly conserved microRNA, and generally be-
lieved to be a multifunctional miRNA involved in cancer [11,12].
Overexpression of miR-21 has been reported in many types of can-
cer cells and regulates cell apoptosis, growth and invasion [11,12].
miR-21 was also found to be induced in macrophages following
LPS challenge. miR-21 also targets PDCD4 expression to suppress
the activation of NF-jB, and inhibit inﬂammatory cytokine expres-
sion while promoting IL-10 production [14]. We report here that
during BCG infection, miR-21 may also directly target IL12 mRNA
to reduce the inﬂammatory response triggered in APCs. Induction
of miR-21 requires activation of the Erk pathway and transcription
factor NF-jB, suggesting the presence of NF-jB binding site in the
promoter region of miR-21. Thus, we suggest two feedback regula-
tions involved in this process: First, activation of NF-jB induces
miR-21 expression, while miR-21 in turn inhibits NF-jB by target-
ing PDCD4. Second, BCG infection induces IL-12 to trigger anti-
Fig. 6. miR-21 promotes DC apoptosis by targeting Bcl2. (A) Apoptosis of BMDCs transfected with miR-21 mimics or inhibitors at day 3 after BCG infection. Data are
representative of three independent experiments. (B) Statistic analysis of the apoptosis in (A). (C) Detection of Bcl-2 protein (up) and mRNA expression (bottom) in BMDCs
differentially transfected with miR-21 mimics or inhibitors with or without BCG infection. (D) Apoptosis of BMDCs co-transfected with miR-21 mimics and Bcl2 siRNA 3 days
post BCG infection. Data are shown as mean ± SD of three independent experiments. ⁄P < 0.05.
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slowly but signiﬁcantly to inhibit prolonged IL-12 production.
These two feedback loops may protect the host from excessive
inﬂammatory responses and protect the host from immunopatho-
genesis. However, this activity may also impair potent anti-myco-
bacterial immunity.
Developing of efﬁcient host Th1 responses is essential to eradi-
cating of mycobacteria [33,34]. Protective immunity is initiated by
a polarized production of type 1 cytokine IL-12 from macrophages
and DCs [35,36]. Humans with mutations in the IL-12 pathway
showed increased susceptibility to tuberculosis infection [37]. IL-
12 expression is regulated by pattern recognition receptors (PRR),
which sense conserved molecular patterns of the microbes. Toll
like receptors (TLR) are a major class of PRRs involved in inducing
IL-12 production [38]. Other signals, such as Dectin-1 [39], have
been shown to induce IL-12 expression. However, there remains
a paucity of information on the post-transcriptional regulation of
IL-12. Recently, Lu et al. revealed in asthma models that loss of
miR-21 suppresses Th2 polarization and reduces asthma in the
lung mainly by targeting Il12p35 [15,16]. However, in their obser-
vation, they found no inﬂuence of TNF, IL-6 expression with miR-
21 inhibition, which was different from our study. Our current re-
sults involving BCG vaccination are mainly consistent with those of
the above studies, and further found that miR-21 may increase APC
apoptosis by targeting Bcl2 mRNA, which may cause the impaired
TNF, IL-6 expression and further impair the Th1 responses trig-
gered by BCG vaccination. In addition, our results also suggested
that mycobacteria may escape from immune attack partiallythrough the upregulation of miR-21 in the lung APCs, which could
serve as potential therapeutic target for Mtb infection.
miR-21 was ﬁrst shown to be an apoptosis suppressor in vari-
ous tumor cell lines [40], and was recognized as an oncogenic miR-
NA. Overexpression of miAR-21 has been observed in most cancer
types and is correlated with the exacerbated tumor proliferation,
invasion and metastasis [11,12]. Subsequent studies have con-
ﬁrmed the anti-apoptotic function of miR-21 in many cancer cells
primarily by indirectly upregulating the anti-apoptotic factor Bcl-2
[41,42]. Several miR-21 target transcripts have been suggested to
explain its anti-apoptotic effect, including programmed cell death
4 (PDCD4) [40,43], tropomyosin 1 (Tpm1) [44], phosphatase and
tensin homolog (Pten) [45], and sprouty homolog 2 (Spry2) [46]
etc., which vary widely in different cell types. However, the exact
mechanisms by which miR-21 regulates Bcl-2 expression remains
unclear. Therefore, identifying direct miR-21 targets may provide
new insight into howmiR-21 controls expression of genes involved
in apoptosis pathways, including Bcl-2.
Although many different cell types reduce Bcl-2 expression and
undergo apoptosis in response to miR-21 inhibition, there is also
report revealing that miR-21 inhibition increases Bcl-2 expression
in MCF7 breast cancer cells [32]. In our study, we found that miR-
21 can directly target the 30UTR of Bcl2 mRNA, and suppress its
expression in BMDCs, resulting in greater cell apoptosis following
BCG infection. However, no pro-apoptotic function of miR-21 was
observed in BMDCs without BCG infection, although both mRNA
and protein level of Bcl2 was suppressed by miR-21. This may be
due to the little spontaneous apoptosis of BMDCs or the low
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duce certain factor(s) that would facilitate miR-21 function, or
other miR-21 target molecules may be functioning in BCG-induced
DC apoptosis in addition to Bcl-2. Therefore, miR-21 may have dif-
ferent target transcripts in different cell types, and act as a pro-
apoptotic or anti-apoptotic factor in these different cells. Although
we have shown that miR-21 can directly suppress Bcl2 mRNA by
binding to the 30UTR in a luciferase reporter assay in HEK293 cells,
we cannot exclude the possibility that miR-21 may decrease Bcl-2
expression by other indirect mechanisms in BMDCs.
During Mtb infection, infected DCs migrate to the draining
mediastinal lymph nodes and initiate anti-mycobacterial adaptive
immunity by priming naïve T cells to become effector and memory
cells [47,48]. Macrophages can also present antigens especially in
the granulomas site to activate effector and memory T cells [48].
The effect of mycobacterial infection on APC function has been
studied extensively. APCs infected by Mtb both in vitro and
in vivo are less efﬁcient in stimulating antigen speciﬁc Th1 cells
than uninfected controls, which may be explained by the sup-
pressed expression of MHC II [49,50]. Our data may further provide
another explanation revealing that induction of miR-21 and its
downregulation of the Th1 responses may also contribute to the
weak priming ability of Mtb-infected APCs. When miR-21 inhibi-
tors were transfected into APCs in vitro, more potent anti-myco-
bacterial T cell responses were triggered both in vitro and in vivo
after injection into the footpad.
In sum, our results found that BCG infection can induce de novo
expression of miR-21 probably through a TLR/Erk/NF-jB pathway.
Inductive miR-21 then directly binds to the 30UTR of Il12p35 and
Bcl2 mRNA, inhibiting IL-12 expression and promoting APC apop-
tosis. Inhibitors of miR-21 prevented IL-12 production frommacro-
phages and DCs, triggering a more potent anti-mycobaterial CD4
and CD8 T cell responses both in vitro and in vivo. Our data sug-
gests a mechanism for the ﬁne-tuning of inﬂammatory responses
triggered by BCG vaccination, and also provides potential targets
that can be used to improve the efﬁcacy of BCG vaccination.
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